University Spinouts

Articles and news on the latest UK university spinouts commercialising innovative technologies, inventions, and intellectual property developed through academic research.


Rising Star: Simon Cartmell of university spin-out Apatech

Apatech, a manufacturer of artificial bone-graft material, has grown sales to £3.1 million from £270,000 in 2005. We interview its CEO Simon Cartmell.


Imperial College London spin-out gets funding

Biopharmaceutical company PolyTherics has secured funding of £2.3 million from a consortium of private equity and venture capital interests.


Xceleron raises £2 million

Drug development company Xceleron has secured £2 million in an early stage funding round led by Close Ventures.


OrthoMimetics in £5 million funding

Biotechnology developer OrthoMimetics has raised £5 million in a Series A funding round, managed by Eden Financial.

Exit Strategies

From labs to riches – How to ensure spin-out success

The difficulty of raising venture capital in recent years has made things much tougher for the entrepreneurial academic looking to turn a scientific breakthrough into a commercial business. However, for a research team that is really convinced that it has a world-beating product on its hands, it is possible to make the transition, but several success factors have to be in place.

Alternative Finance for Business

A tale of two spin-outs

The reputation and quality of British science is globally recognised. But can it be converted into the creation of world-beating businesses? Cliff Jones and Kevin Matthews provide two good reasons to be optimistic.


Cash hit for IXICO

IXICO, a spin-out company from London University, has drummed up £930,000 in its first institutional fundraising, from The Capital Fund and a number of private investors.

Mergers & Acquisitions

University spin-outs and venture capital funds come together

Investors are increasingly keen to back cutting-edge technology developed at UK universities, but entrepreneurial talent is what is really needed to make such ventures commercially successful.


Oxonica seeks £15m

Nanotechnology application developer Oxonica is looking to raise £15 million in a flotation that will see the fast-growing company join AIM in April with a possible valuation of £50 million.


Proximagen proposes £30m IPO

Drug developer Proximagen, a spin out from King’s College, will join AIM at the end of the month with a £30 million starting price tag.